MDV3100 (Enzalutamide) is authorized as the anti-prostate cancer drug (Gibbons et al., 2015), and inhibits nuclear translocation of AR, and coactivator recruitment (Tran et al., 2009). The gene discussed is AR; the disease is prostate carcinoma.